RECRUITING

Monetary Incentive Delay Task for Probing Reward-related Neural Processes

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

150 males and 150 females ages 14-17 years-old will be enrolled in an observational, longitudinal study. There are three planned in-person visits: a baseline assessment, an 18-month follow-up, and a 36-month follow-up. The in-person visits will include assessment of substance use and other individual differences (e.g., reward function, psychiatric history), neuromelanin-sensitive MRI, as well as functional brain activation collected while the participant is at rest (resting-state fMRI) and while the participant completes a Monetary Incentive Delay task. Subjects will also be asked to complete past 90-day substance use assessments remotely every 90 days for 36 months.

Official Title

Neuromelanin MRI: A Tool for Non-invasive Investigation of Dopaminergic Abnormalities in Adolescent Substance Use

Quick Facts

Study Start:2024-04-06
Study Completion:2028-11-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06369623

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:14 Years to 17 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * (A) Males and females ages 14-17 years-old; (B) English-speaking for assent and interview completion, and (C) capacity to provide assent. For parents, the inclusion criteria will be (D) willing and capacity to provide parental permission/consent.
  1. * (A) current (within 6 months) use of medication that may affect cerebral function; (B) history of severe medical or neurological illness, including stroke or seizure; (C) history of head trauma with loss of consciousness; (D) presence of metal in the body; (E) pregnancy or breastfeeding; (F) recent drug or alcohol use determined by positive urine toxicology or breathalyzer (to validate self-report assessment of substance use history); (G) lifetime use of psychotropic or other medication that could likely influence dopamine function, namely stimulant medication or antipsychotic medication.

Contacts and Locations

Study Contact

Greg Perlman, PhD
CONTACT
1-631-638-1922
greg.perlman@stonybrookmedicine.edu
Lu-Ann Kozlowski, BSN
CONTACT
1-631-632-9036
lu-ann.kozlowski@stonybrook.edu

Study Locations (Sites)

Stony Brook Medicine
Stony Brook, New York, 11794
United States

Collaborators and Investigators

Sponsor: Stony Brook University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-06
Study Completion Date2028-11-30

Study Record Updates

Study Start Date2024-04-06
Study Completion Date2028-11-30

Terms related to this study

Additional Relevant MeSH Terms

  • Adolescent Development